SPRO Earnings Date & History
Spero Therapeutics Inc (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Aug 19, 2026 at 7:34 PM ET
Spero Therapeutics Inc
Biotechnology
- Next earnings date
- Wednesday, November 11, 2026
- Reporting session
- Time TBD
- EPS estimate
- $-0.16
- Revenue estimate
- —
SPRO earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Wednesday, August 12, 2026 | Q2 2026 | $-0.17 | $-0.16 | +7.7% | $0 |
| Wednesday, May 13, 2026 | Q1 2026 | $-0.18 | $-0.13 | +29.2% | $260,000 |
| Thursday, March 26, 2026 | Q4 2025 | $-0.20 | $0.53 | +359.8% | $41.3M |
| Thursday, November 13, 2025 | Q3 2025 | $-0.26 | $-0.13 | +49.0% | $5.4M |
| Tuesday, August 12, 2025 | Q2 2025 | $-0.39 | $-0.03 | +92.3% | $14.2M |
What the market is watching in SPRO's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next SPRO earnings date?
- Spero Therapeutics Inc is scheduled to report on Wednesday, November 11, 2026 (Time TBD). Dates can change until the company confirms them.
- Does SPRO report before or after the market?
- The next report is scheduled time tbd.
- What EPS is expected for SPRO?
- Consensus EPS for the upcoming quarter is $-0.16.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
SPRO earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.